KAS
ESPR

Kestra Advisory Services’s Esperion Therapeutics ESPR Stock Holding History

Kestra Advisory Services’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,570
Closed -$35.4K – 3498
2025
Q4 		$35.4K Buy
+9,570
New +$30.9K ﹤0.01% 4179
2022
Q2 		– Sell
-41,570
Closed -$193K – 2160
2022
Q1 		$193K Buy
41,570
+8,870
+27% +$38K ﹤0.01% 1861
2021
Q4 		$164K Buy
+32,700
New +$262K ﹤0.01% 1901

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kestra Advisory Services's ESPR Position: Q1 2026 in Review

Kestra Advisory Services sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 9,570 shares — an estimated $35.4K sold.

Kestra Advisory Services first reported a position in ESPR in Q4 2021 and held it in 3 quarters. The position peaked at $193K in Q1 2022. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Kestra Advisory Services reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 9,570 Esperion Therapeutics shares in Q1 2026, an estimated $35.4K.
  • Kestra Advisory Services first reported a position in Esperion Therapeutics in Q4 2021 and held it in 3 quarters.
  • Kestra Advisory Services's Esperion Therapeutics position peaked at $193K in Q1 2022.
  • 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.